实体恶性肿瘤患者ICU收治模式与结局在癌症治疗变革中的变化
该回顾性单中心研究纳入2007-2018年12年间1525例需非计划ICU收治的成人实体恶性肿瘤患者,分析收治模式与结局趋势。结果显示转移性疾病比例从2007-2008年的48.6%升至2017-2018年的60.2%(p=0.004),药物或操作相关不良事件导致的危重症从8.8%升至16%(p=0.01);ICU生存率77.4%,研究期间无显著变化;1279例完整随访患者1年生存率33.2%。ICU死亡独立决定因素包括转移性疾病、治疗中癌症进展、因特异性并发症收治及器官衰竭程度;ICU幸存者1年死亡独立相关因素包括肺癌、转移性疾病、治疗中癌症进展、因特异性并发症收治及放弃生命支持治疗的决定。
要点
- 1525例实体恶性肿瘤患者中,转移性疾病比例从2007-2008年48.6%升至2017-2018年60.2%(p=0.004)。
- 药物或操作相关不良事件导致的ICU收治比例从2007-2008年8.8%升至2017-2018年16%(p=0.01)。
- ICU生存率77.4%,研究期间无显著变化;1279例完整随访患者1年生存率33.2%。
- ICU死亡独立决定因素:转移性疾病、治疗中癌症进展、因特异性并发症收治、器官衰竭程度(有创和无创通气、正性肌力药/血管升压药、肾脏替代治疗及SOFA评分)。
- ICU幸存者1年死亡独立相关因素:肺癌、转移性疾病、治疗中癌症进展、因特异性并发症收治及放弃生命支持治疗的决定。
适用人群与场景
- 成人实体恶性肿瘤患者,需非计划ICU收治,研究期间为2007-2018年。
- 肺癌和胃肠道肿瘤为两大主要肿瘤部位。
研究设计与关键结果
- 研究类型:回顾性单中心研究,为期12年(2007-2018年),纳入1525例成人实体恶性肿瘤需非计划ICU收治的患者。
- 收治模式分类:特异性(直接与基础癌症相关)、非特异性、药物或操作相关不良事件。
- 转移性疾病比例从2007-2008年48.6%升至2017-2018年60.2%(p=0.004)。
- 药物或操作相关不良事件导致的ICU收治比例从2007-2008年8.8%升至2017-2018年16%(p=0.01)。
- ICU入科时危重症粗略严重程度随时间无变化。
- ICU生存率77.4%,研究期间无显著变化。
- 1279例完整随访患者中,1年生存率33.2%。
- ICU死亡独立决定因素:转移性疾病、治疗中癌症进展、因特异性并发症收治及器官衰竭程度(有创和无创通气、正性肌力药/血管升压药、肾脏替代治疗和SOFA评分)。
证据类型、等级与局限
- 证据类型:回顾性单中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管实体恶性肿瘤常为晚期且转移,但令人鼓舞的短期和长期结局应有助于改变对危重癌症患者的悲观看法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Major therapeutic advances including immunotherapy and targeted therapies have been changing the face of oncology and resulted in improved prognosis as well as in new toxic complications. The aim of this study is to appraise the trends in intensive care unit (ICU) admissions and outcomes of critically ill patients with solid malignancies. We performed a retrospective single-centre study over a 12-year period (2007-2018) including adult patients with solid malignancies requiring unplanned ICU admission. Admission patterns were classified as: (i) specific if directly related to the underlying cancer; (ii) non-specific; (iii) drug-related or procedural adverse events.
RESULTS: 1525 patients were analysed. Lung and gastro-intestinal tract accounted for the two main tumour sites. The proportion of patients with metastatic diseases increased from 48.6% in 2007-2008 to 60.2% in 2017-2018 (p = 0.004). Critical conditions were increasingly related to drug- or procedure-related adverse events, from 8.8% of ICU admissions in 2007-2008 to 16% in 2017-2018 (p = 0.01). The crude severity of critical illness at ICU admission did not change over time. The ICU survival rate was 77.4%, without any significant changes over the study period. Among the 1279 patients with complete follow-up, the 1-year survival rate was 33.2%. Independent determinants of ICU mortality were metastatic disease, cancer in progression under treatment, admission for specific complications and the extent of organ failures (invasive and non-invasive ventilation, inotropes/vasopressors, renal replacement therapy and SOFA score). One-year mortality in ICU-survivors was independently associated with lung cancer, metastatic disease, cancer in progression under treatment, admission for specific complications and decision to forgo life-sustaining therapies.
CONCLUSION: Advances in the management and the prognosis of solid malignancies substantially modified the ICU admission patterns of cancer patients. Despite underlying advanced and often metastatic malignancies, encouraging short-term and long-term outcomes should help changing the dismal perception of critically ill cancer patients.
参考来源
- Vigneron C, Charpentier J, Valade S, et al. Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment. Ann Intensive Care. 2021. PMID: 34951668. doi:10.1186/s13613-021-00968-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。